Literature DB >> 10074125

A second-site mutation that restores replication of a Tat-defective human immunodeficiency virus.

K Verhoef1, B Berkhout.   

Abstract

We previously constructed a large set of mutants of the human immunodeficiency virus type 1 (HIV-1) regulatory protein Tat with conservative amino acid substitutions in the activation domain. These Tat variants were analyzed in the context of the infectious virus, and several mutants were found to be defective for replication. In an attempt to obtain second-site suppressor mutations that could provide information on the Tat protein structure, some of the replication-impaired viruses were used as a parent for the isolation of revertant viruses with improved replication capacity. Sequence analysis of revertant viruses frequently revealed changes within the tat gene, most often first-site reversions either to the wild-type amino acid or to related amino acids that restore, at least partially, the Tat function and virus replication. Of 30 revertant cultures, we identified only one second-site suppressor mutation. The inactive Y26A mutant yielded the second-site suppressor mutation Y47N that partially restored trans-activation activity and virus replication. Surprisingly, when the suppressor mutation was introduced in the wild-type Tat background, it also improved the trans-activation function of this protein about twofold. We conclude that the gain of function measured for the Y47N change is not specific for the Y26A mutant, arguing against a direct interaction of Tat amino acids 26 and 47 in the three-dimensional fold of this protein. Other revertant viruses did not contain any additional Tat changes, and some viruses revealed putative second-site Tat mutations that did not significantly improve Tat function and virus replication. We reason that these mutations were introduced by chance through founder effects or by linkage to suppressor mutations elsewhere in the virus genome. In conclusion, the forced evolution of mutant HIV-1 genomes, which is an efficient approach for the analysis of RNA regulatory motifs, seems less suited for the analysis of the structure of this small transcription factor, although protein variants with interesting properties can be generated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10074125      PMCID: PMC104035     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations.

Authors:  M A Martinez; J P Vartanian; S Wain-Hobson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

2.  Structural studies of HIV-1 Tat protein.

Authors:  P Bayer; M Kraft; A Ejchart; M Westendorp; R Frank; P Rösch
Journal:  J Mol Biol       Date:  1995-04-07       Impact factor: 5.469

3.  NMR structure of a biologically active peptide containing the RNA-binding domain of human immunodeficiency virus type 1 Tat.

Authors:  A Mujeeb; K Bishop; B M Peterlin; C Turck; T G Parslow; T L James
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

4.  Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

Authors:  N K Back; M Nijhuis; W Keulen; C A Boucher; B O Oude Essink; A B van Kuilenburg; A H van Gennip; B Berkhout
Journal:  EMBO J       Date:  1996-08-01       Impact factor: 11.598

5.  Reduced replication of human immunodeficiency virus type 1 mutants that use reverse transcription primers other than the natural tRNA(3Lys).

Authors:  A T Das; B Klaver; B Berkhout
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

6.  Evolution of the human immunodeficiency virus type 1 long terminal repeat promoter by conversion of an NF-kappaB enhancer element into a GABP binding site.

Authors:  K Verhoef; R W Sanders; V Fontaine; S Kitajima; B Berkhout
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

7.  Complete 1H nuclear magnetic resonance assignments and structural characterization of a fusion protein of the alpha-amylase inhibitor tendamistat with the activation domain of the human immunodeficiency virus type 1 Tat protein.

Authors:  J Freund; L Vértesy; K P Koller; V Wolber; D Heintz; H R Kalbitzer
Journal:  J Mol Biol       Date:  1995-07-28       Impact factor: 5.469

8.  Presence of exon splicing silencers within human immunodeficiency virus type 1 tat exon 2 and tat-rev exon 3: evidence for inhibition mediated by cellular factors.

Authors:  B A Amendt; Z H Si; C M Stoltzfus
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

9.  Human immunodeficiency viruses regulated by alternative trans-activators: genetic evidence for a novel non-transcriptional function of Tat in virion infectivity.

Authors:  L M Huang; A Joshi; R Willey; J Orenstein; K T Jeang
Journal:  EMBO J       Date:  1994-06-15       Impact factor: 11.598

10.  Evolution of a disrupted TAR RNA hairpin structure in the HIV-1 virus.

Authors:  B Klaver; B Berkhout
Journal:  EMBO J       Date:  1994-06-01       Impact factor: 11.598

View more
  16 in total

1.  Selection of TAR RNA-binding chameleon peptides by using a retroviral replication system.

Authors:  Baode Xie; Valerie Calabro; Mark A Wainberg; Alan D Frankel
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

2.  Mutual information analysis reveals coevolving residues in Tat that compensate for two distinct functions in HIV-1 gene expression.

Authors:  Siddharth S Dey; Yuhua Xue; Marcin P Joachimiak; Gregory D Friedland; John C Burnett; Qiang Zhou; Adam P Arkin; David V Schaffer
Journal:  J Biol Chem       Date:  2012-01-17       Impact factor: 5.157

Review 3.  HIV-1 evolution: frustrating therapies, but disclosing molecular mechanisms.

Authors:  Atze T Das; Ben Berkhout
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2010-06-27       Impact factor: 6.237

4.  Repair of a Rev-minus human immunodeficiency virus type 1 mutant by activation of a cryptic splice site.

Authors:  K Verhoef; P S Bilodeau; J L van Wamel; J Kjems; C M Stoltzfus; B Berkhout
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  Strict control of human immunodeficiency virus type 1 replication by a genetic switch: Tet for Tat.

Authors:  K Verhoef; G Marzio; W Hillen; H Bujard; B Berkhout
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

6.  Genetic and functional heterogeneity of CNS-derived tat alleles from patients with HIV-associated dementia.

Authors:  Daniel Cowley; Lachlan R Gray; Steven L Wesselingh; Paul R Gorry; Melissa J Churchill
Journal:  J Neurovirol       Date:  2010-11-30       Impact factor: 2.643

Review 7.  Cure and Long-Term Remission Strategies.

Authors:  Luisa Mori; Susana T Valente
Journal:  Methods Mol Biol       Date:  2022

8.  A naturally occurring substitution in human immunodeficiency virus Tat increases expression of the viral genome.

Authors:  Syed M Reza; Lin-Ming Shen; Rupa Mukhopadhyay; Mihaela Rosetti; Tsafi Pe'ery; Michael B Mathews
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  Replication of human immunodeficiency viruses engineered with heterologous Tat-transactivation response element interactions.

Authors:  Baode Xie; Mark A Wainberg; Alan D Frankel
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

10.  Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias.

Authors:  Rienk E Jeeninga; Barbara Jan; Henk van den Berg; Ben Berkhout
Journal:  Retrovirology       Date:  2006-09-27       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.